Dutch biotech firm, VectorY, has raised $138m to advance its antibody technology in the treatment of neurodegenerative diseases, particularly ALS. By targeting the misfolded protein TDP-43 with antibodies, VectorY’s drug therapy could potentially tackle an aggressive form of ALS that has previously proved difficult to treat. The funding will be used to push the lead programme, VTX-002, into clinical trials which are hoped to begin in early 2025.
SANS Stormcast Thursday, October 30th, 2025: Memory Only Filesystems Forensics; Azure Outage; docker-compose patch
How to Collect Memory-Only Filesystems on Linux Systems Getting forensically sound copies of memory-only file systems on Linux can be tricky, as tools like dd
